Please ensure Javascript is enabled for purposes of website accessibility

Why AbbVie Stock Sank in September

By George Budwell – Oct 7, 2021 at 10:30AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A regulatory setback weighed on the drugmaker's shares last month.

What happened

Shares of the Illinois-based AbbVie (ABBV -0.14%) sank by an eye-catching 10.7% last month, according to data provided by S&P Global Market Intelligence. That's equivalent to a $20 billion drop in market capitalization. What caused investors to hit the panic button on the drugmaker's stock last month? Early on in September, the U.S. Food and Drug Administration issued a wave of new warnings for a class of drugs known as JAK inhibitors.

The warning stemmed from a large safety-related study showing that patients taking Pfizer's JAK inhibitor medication Xeljanz, an arthritis drug, were at increased risk of heart attack, stroke, cancer, blood clots, and death. AbbVie's next-generation rheumatoid arthritis med, Rinvoq, received a similar warning from the FDA because it belongs to the same class of medications as Pfizer's drug. Investors apparently took this regulatory setback to mean that AbbVie's new growth product will ultimately be negatively impacted by this news. 

A person covering their face in front of a laptop.

Image source: Getty Images.

So what

AbbVie has been going through a long-winded metamorphosis for a number of years. The biopharma has been working diligently to build a portfolio of newer growth products to soften the blow from the patent expiration for Humira, an autoimmune disease medication used for a laundry list of conditions. Humira was formerly the world's best-selling pharma product of all time before the COVID-19 pandemic, and a big reason AbbVie has been one of the fastest-growing pharma companies over the prior decade.

Rinvoq, unfortunately, was a key part of AbbVie's plan. Wall Street estimated that the drug could bring in over $10 billion in sales a little past the middle of the decade. This new warning, however, could slow of the adoption rate for this entire class of potent medications. That's not guaranteed to happen of course. But the market seems to think this dire outcome is a foregone conclusion, at least based on how AbbVie's stock has reacted to this news so far.  

Now what

Is AbbVie's stock a bad news buy? Prior to this pullback, I thought AbbVie's stock was getting a little overheated. The drugmaker's shares were up by close to 17% for the year (when including dividends as part of the total return), and it sported a price-to-earnings ratio well over 30. Even after this drop, though, AbbVie's shares aren't exactly cheap (with trailing P/E of about 30), and this JAK regulatory news will take a while to fully understand. All told, investors might be better off to sidestep this beaten-down biotech stock for the time being.  

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Stock Quote
AbbVie
ABBV
$158.20 (-0.14%) $0.23
Pfizer Stock Quote
Pfizer
PFE
$49.49 (-0.16%) $0.08

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.